Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00322556 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Agammaglobulinemia
IgG Deficiency
Common Variable Immunodeficiency

Interventions

DRUG: Immunoglobulins Intravenous (Human)

Sponsor

CSL Behring